DOI: 10.5061/dryad.pb7j7
title: Data from: Phosphorescence monitoring of hypoxic microenvironment in solid-tumors to evaluate chemotherapeutic effects using the hypoxia-sensitive iridium (III) coordination compound

description: Objectives: To utilize phosphorescence to monitor hypoxic microenvironment
 in solid-tumors and investigate cancer chemotherapeutic effects in vivo.
 Methods: A hypoxia-sensitive probe named BTP was used to monitor hypoxic
 microenvironment in solid-tumors. The low-dose metronomic treatment with
 cisplatin was used in anti-angiogenetic chemotherapeutic programs. The
 phosphorescence properties of BTP were detected by a spectrofluorometer.
 BTP cytotoxicity utilized cell necrosis and apoptosis, which were
 evaluated by trypan blue dye exclusion and Hoechst33342 plus propidium
 iodide assays. Tumor-bearing mouse models of colon adenocarcinoma were
 used for tumor imaging in vivo. Monitoring of the hypoxic microenvironment
 in tumors was performed with a Maestro 2 fluorescence imaging system.
 Tumor tissues in each group were harvested regularly and treated with
 pathological hematoxylin and eosin and immunohistochemical staining to
 confirm imaging results. Results: BTP did not feature obvious cytotoxicity
 for cells, and tumor growth in low-dose metronomic cisplatin treated mice
 was significantly inhibited by chemotherapy. Hypoxic levels significantly
 increased due to cisplatin, as proven by the expression level of related
 proteins. Phosphorescence intensity in the tumors of mice in the cisplatin
 group was stronger and showed higher contrast than that in tumors of
 saline treated mice. We develop a useful phosphorescence method to
 evaluate the chemotherapeutic effects of cisplatin. The proposed method
 shows potential as a phosphorescence imaging approach for evaluating
 chemotherapeutic effects in vivo, especially anti-angiogenesis.
description: Figure
 2bFigure 2b. The
 relationship between the pO2 and phosphoresce
 intensity.Figure
 2cFigure 2c. Cytotoxicity
 evaluation of BTP: Trypan blue dye exclusion assay to measure the cell
 necrosis rate and Hoechst 33342 plus propidium iodide (PI) assay to
 measure the cell apoptosis rate (n=10).Figure
 4aFigure 4a. The growth
 curves of CT-26 xenografts after transplantation into BALB/c nude mice
 treated with saline and cisplatin (n=6).Figure
 4bFigure 4b. The
 phosphorescence intensity of tumor imaging of CT-26 xenografts after
 transplantation into BALB/c nude mice treated with saline and cisplatin
 (n=6).Saline (100 µL) or cisplatin (1 mg/kg, 100 µL).Figure
 4cFigure 4c. The
 quantitative data curves of immunohistochemical stain of HIF-1a in
 tumor-bearing mice treated with saline and cisplatin, respectively
 (n=3).Figure
 4dFigure 4d. The
 quantitative data curves of immunohistochemical stain of VEGFin
 tumor-bearing mice treated with saline and cisplatin, respectively
 (n=3).Figure
 S1Figure S1. The
 phosphorescence intensity of tumor imaging of CT-26 xenografts after
 transplantation into BALB/c nude mice treated with saline and cisplatin
 with different dose or combined drug treatment. Saline (100 µL),cisplatin
 (3 mg/kg, 100 µL), anti-VEGF (5 mg/kg, 100µL) or combination (cisplatin 3
 mg/kg+anti-VEGF 5 mg/kg, 100 µL).